Home/Pipeline/STP-001

STP-001

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

STipe Therapeutics

About STipe Therapeutics

STipe Therapeutics is a private, preclinical-stage biotech founded in 2017 and based in Copenhagen, Denmark. The company is developing a proprietary platform of small molecule STING agonists engineered for targeted intratumoral delivery to reshape the tumor microenvironment and generate systemic anti-cancer immunity. Its lead program is advancing towards clinical trials, supported by venture capital funding and strategic research collaborations. STipe's approach aims to unlock the full potential of STING activation as a cornerstone of next-generation immuno-oncology combinations.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed